Resource use and cost of hepatitis C-related care

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 10, 2012, Pages 1191-1198

  Nevens, Frederik ^a   Colle, Isabelle ^b   Michielsen, Peter ^c   Robaeys, Geert ^d   Moreno, Christophe ^e   Caekelbergh, Karin ^f   Lamotte, Mark ^f   Wyffels, Veronique ^g  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UZ Antwerp   (Belgium)

^d DEPARTMENT OF CARDIOLOGY   (Belgium)

^e ERASME HOSPITAL   (Belgium)

^f IQVIA   (United States)

^g Janssen Cilag EMEA Belgium   (Belgium)

Author keywords

chronic hepatitis C; decompensated cirrhosis; hepatocellular carcinoma; liver transplantation; medical cost

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CHEMOEMBOLIZATION; COMORBIDITY; DECOMPENSATED LIVER CIRRHOSIS; DRUG ABUSE; DRUG COST; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GENOTYPE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEPATITIS C; HOSPITALIZATION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTICENTER STUDY; PATIENT CARE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BELGIUM; CARCINOMA, HEPATOCELLULAR; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOSPITALIZATION; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84866333892     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283566658     Document Type: Article

References (28)

1. World Health Organization. Global Alert and Response-Hepatitis. Available at: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index3.html [Accessed 1 October 2011].
2. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-472. (Pubitemid 27078833)
3. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity and mortality. BMC Public Health 2009; 9:34.
4. European Association on the Studies on the Liver (EASL). EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999; 31 (Suppl 1):3-8.
5. Beutels M, Van Damme P, Aelvoet W, Desmyter J, Dondeyne F, Goilav C, et al. Prevalence of hepatitis A, B and C in the Flemish population. Eur J Epidemiol 1997; 13:275-280. (Pubitemid 27306072)
6. Van Vlierberghe H, Colle I, Henrion J, Michielsen P, Delwaide J, Reynaert H, et al. Belgian Assocation for the Study of the Liver steering committee. The HepCar registry: report on a one-year registration program of hepatocellular carcinoma in Belgium. What is the daily practice in HCC? Acta Gastroenterol Belg 2005 68:1-9.
7. Adler M, De Pauw F, Vereerstraeten Fancello A, Lerut J, Starkel P, Van Vlierberghe H, et al. Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system. Liver Transpl 2008; 14:526-533. (Pubitemid 351524409)
8. Grieve R, Roberts J. Economic evaluation for hepatitis C. Acta Gastroenterol Belg 2002; 65:104-108.
9. Jusot JF, Colin C. Cost-effectiveness analysis of strategies for hepatitis C screening in French blood recipients. Eur J Public Health 2001; 11: 373-379. (Pubitemid 33130056)
10. Wright M, Grieve R, Roberts J, Main J, Thomas HC. UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: randomized controlled trial and economic evaluation. Health Technol Assess 2006; 10:1-113, iii.
11. Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006; 55: 1332-1338. (Pubitemid 44277366)
12. Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, et al. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics 2009; 27:341-354.
13. Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg 2002; 65: 110-111. (Pubitemid 34742472)
14. Nevens F. Resource analysis of somatostatin in the treatment of bleeding esophageal varices. Digestion 1999; 60 (Suppl 3):35-37. (Pubitemid 29537545)
15. Kleter B, Brouwer JT, Nevens F, van Doorn LJ, Elewaut A, Versieck J, et al. Hepatitis C virus genotypes: epidemiological and clinical associations. Benelux Study Group on Treatment of Chronic Hepatitis C. Liver 1998; 18:32-38. (Pubitemid 28127755)
16. Fattovich G, Ribero ML, Pantalena M, Diodati G, Almasio P, Nevens F, et al. Eurohep Study Group on Viral Hepatitis. Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. J Viral Hepat 2001; 8:206-216. (Pubitemid 32506634)
17. Langlet P, D'Heygere F, Henrion J, Adler M, Delwaide J, Van Vlierberghe H, et al. Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients. Aliment Pharmacol Ther 2009; 30: 352-363.
18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293. (Pubitemid 26260021)
19. RIZIV/INAMI. Drugs and medical provisions. Nomenclature medical provisions. Available at: http://www.riziv.be [Accessed 16 August 2010].
20. Technical Cell Database. Financial feedback per pathology-national data-data 2007. Available at: https://tct.fgov.be/etct/index.html [Accessed 16 August 2010].
21. Schwierz C, Thiry N, Van de Sande S, Gamil M, Nevens F, Colle I, Horsmans Y, Hulstaert F. Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium-Part 2. Health Technology Assessment (HTA). Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE). 2011. Reports 157A. D/2011/10.273/27.
22. Lamotte M, Annemans L, Lamberts G, Michielsen D, Nicolas H, Van Cangh P, et al. The cost of complicated acute urinary retention. Retrospective analysis in Belgium. Rev Med Liège 2005; 60:875-881. (Pubitemid 43001230)
23. Moeremans K, Caekelbergh K, Spaepen E, Annemans L, Dhawan R. Cost drivers in multiple myeloma treatment-a 2 year analysis from a multicountry retroprojected chart review. Abstract & podium presentation (code UH2). Ispor 8th Annual European Congress. Florence, Italy, 6 November 2005.
24. Annemans L, Caekelbergh K, Roelandts R, Boonen H, Leys C, Nikkels F, et al. Real life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. Eur J Dermatol 2008; 18:539-546.
25. Caekelbergh K, Lamotte M, Dratwa M, Bogaert AM, Bouman K, Laplante S. Resource use and cost of patients undergoing dialysis in Belgium. Abstract & poster presentation. Ispor 13th Annual European Congress. Prague, Czech Republic, November 2010 (code PUK15).
26. Dusheiko M, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995; 22:1863-1872.
27. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000; 4:1-67.
28. Wong JB. Hepatitis C. Cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006; 24: 661-672. (Pubitemid 43998819)